View Financial HealthThis company is no longer activeThe company may no longer be operating, as it may be out of business. Find out why through their latest events.See Latest EventsDanimer Scientific 배당 및 자사주 매입배당 기준 점검 0/6Danimer Scientific 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-157.4%자사주 매입 수익률총 주주 수익률-157.4%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Apr 18+ 1 more updateBidding Procedure Approved for Danimer Scientific, Inc.The US Bankruptcy Court gave an order approving the bidding procedures relating to the sale of the substantially all the assets of Danimer Scientific, Inc. on April 17, 2025. The Court approved for the sale of substantially all the assets to the successful bidder through auction. To qualify as a qualified bidder, interested parties should submit their bids by May 2, 2025, along with good-faith deposit in the amount of 10% of the bid price. The initial minimum overbid should be at least $0.5 million. If the debtor receives any qualified bids, then it would hold an auction for its assets on May 5, 2025. At the auction, the subsequent bids would be in increments of $0.5 million. The stalking horse bidder would be entitled to a break-up fee of 3%. The sale hearing is scheduled for May 12, 2025. Sale closing is on May 16, 2025.공시 • Apr 15Motion for sale of De Minimis Asset Sale Approved for Danimer Scientific, Inc.The US Bankruptcy Court gave an order approving the sale procedures relating to the sale of De Minimis assets of Danimer Scientific, Inc on April 14, 2025. As per the order the debtors is authorized to sell de minimis assets for $0.25 million or less in total consideration or value in one or a series of related transactions without further notice or court approval after providing notice of the sale to certain parties in accordance with the following procedures. With regard to a De Minimis transaction with a net selling price less than or equal to $2 million, the debtor shall give written notice of each de Minimis transaction to notice parties. The sale notice shall be filed and sent to the notice parties by e-mail, facsimile, or first-class mail at least 7 business days prior to the closing of such de Minimis transaction. With regard to a De Minimis Transaction with a selling price of greater than $2 million, the debtor shall give a sale notice to the notice parties and all other parties required receiving notice under Bankruptcy Rule 2002(a) (2). The sale notice shall be filed and sent to the 2002 parties by e-mail, facsimile, or first-class mail at least 7 calendar days prior to the closing of such de Minimis transaction. Any objections to the De Minimis Transaction must be in writing, state the grounds for the objection with specificity, and be filed and served so as to be actually received on or before the Closing Date. If a sale objection is properly filed and served by the sale objection deadline, and the debtor and the objecting party are unable to reach an agreement among themselves, then the relevant de Minimis asset shall be sold or otherwise transferred only upon further order of this court, after notice and a hearing; provided, however, that the debtor, with the agreement of the relevant proposed counterparty, may consummate any portion of the de Minimis transaction that is not the subject of a sale objection on or after the expiration of the sale objection deadline. If no sale objection is properly filed and served by the sale objection deadline, then the debtor, without further order of the court, is authorized, but not directed, to consummate the de Minimis transaction immediately, and take such other actions as necessary to close such transaction and collect the proceeds thereof.공시 • Mar 28Motion for Asset Sale Filed by Danimer Scientific, Inc.Danimer Scientific, Inc filed a motion in the US Bankruptcy Court for the sale of its substantially all its assets on March 27, 2025. The debtor seeks the Court’s approval for the sale of its substantially all its assets to successful bidder. To qualify as a qualified bidder, interested parties should submit their bids by May 2, 2025, along with good-faith deposit in the amount of 10% of the bid price. The initial minimum overbid should be at least $0.5 million. The debtor has scheduled an auction on May 5, 2025. At the auction, the subsequent bids would be in increments of $0.5 million. The stalking horse bidder would be entitled to a break-up fee of 3%. The sale hearing is scheduled for May 12, 2025. Sale closing is on May 16, 2025.공시 • Mar 19+ 1 more updateMotion for Joint Administration Filed by Danimer Scientific, Inc.Danimer Scientific, Inc., along with its affiliates, filed a motion for joint administration of their Chapter 11 bankruptcy cases in the US Bankruptcy Court on March 18, 2025. As per the motion, the debtor seeks the joint administration of the cases of its affiliates, Danimer Bioplastics, Inc., Danimer Scientific Holdings, LLC, Danimer Scientific Kentucky, Inc., Danimer Scientific Manufacturing, Inc., Danimer Scientific, L.L.C. Meredian Bioplastics, Inc., Meredian Holdings Group, Inc., Meredian, Inc. and Novomer, Inc., with its own case for administrative and procedural purposes. Danimer Scientific, Inc. has been proposed as the lead debtor.공시 • Dec 18Danimer Scientific, Inc. announced that it expects to receive $11.25 million in fundingDanimer Scientific, Inc. announced that it has entered into a super senior secured uninsured promissory note agreement with certain lenders under its existing term loan financing agreement, as well as certain additional lenders for a secured loan for a principal amount of $11,250,000 in exchange for cash, net of a 5% upfront fee and other fees and expenses on December 17, 2024. The secured loan matures on December 17, 2026, and accrues interest at 15% per annum, which interest shall be paid in kind on a quarterly basis. Prepayment of the secured loan is subject to payment of premiums of (i) prior to December 17, 2025, 30% and (ii) on or after December 17, 2025, and before maturity, 10%.공시 • Dec 04Danimer Scientific, Inc. Announces Resignation of Cynthia Cohen as A DirectorDanimer Scientific, Inc. announced that effective as of December 1, 2024, Cynthia Cohen resigned as a director of the Company. Ms. Cohen’s resignation was not because of any disagreement with the Company.공시 • Nov 16Danimer Scientific, Inc. announced delayed 10-Q filingOn 11/15/2024, Danimer Scientific, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Nov 05Danimer Scientific Announces Intention to Complete a Reverse Stock Split to Regain Compliance with the Price Criteria of Section 802.01C of the NYSE Listed Company ManualDanimer Scientific, Inc. announced that, following approval by the Company's stockholders and its Board of Directors, the Company will effect a reverse stock split ('Reverse Stock Split') of Danimer's Class A common stock, par value $0.0001 per share ('Common Stock'), at a ratio of 1-for-40 (the 'Reverse Stock Split Ratio'), which ratio was determined by the Board of Directors from within a range of ratios authorized by the stockholders. The Reverse Stock Split is expected to become effective on November 12, 2024, after close of trading on the New York Stock Exchange ('NYSE'). The Common Stock is expected to begin trading on a split-adjusted basis when the markets open on November 13, 2024, under the existing trading symbol 'DNMR' and new CUSIP number (236272 407). The Company believes the Reverse Stock Split will increase the price per share of the Common Stock and thus enable it to regain compliance with the price criteria of Section 802.01C of the NYSE Listed Company Manual (the 'Minimum Share Price Rule').Board Change • Nov 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Special Advisor & Director Stephen Croskrey was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.공시 • Oct 28Danimer Scientific Announces Second Circuit Court Affirms Dismissal of Class Action LawsuitDanimer Scientific, Inc. announced that, on September 27, 2024, the United States Court of Appeals for the Second Circuit affirmed the 2023 Order of the United States District Court for the Eastern District of New York dismissing a previously disclosed putative class action complaint captioned In re Danimer Scientific, Inc. Securities Litigation. Subsequently, the plaintiffs in the three shareholder derivative cases that had been pending in state and federal courts in Delaware, which cases had been stayed pending the outcome of the Second Circuit case, dismissed their complaints.공시 • Oct 15+ 2 more updatesDanimer Scientific, Inc. to Report Q3, 2024 Results on Nov 14, 2024Danimer Scientific, Inc. announced that they will report Q3, 2024 results After-Market on Nov 14, 2024Reported Earnings • Aug 09Second quarter 2024 earnings released: US$0.20 loss per share (vs US$0.39 loss in 2Q 2023)Second quarter 2024 results: US$0.20 loss per share (improved from US$0.39 loss in 2Q 2023). Revenue: US$7.63m (down 41% from 2Q 2023). Net loss: US$22.7m (loss narrowed 42% from 2Q 2023). Revenue is forecast to grow 44% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Chemicals industry in Germany.공시 • Aug 09Danimer Scientific, Inc. Provides Financial Guidance for the Second Quarter of Fiscal 2025Danimer Scientific, Inc. provides financial guidance for the second quarter of fiscal 2025. For the period, the company expects annualized PHA revenues to more than triple, based solely on demand from existing customer relationships and their indicated volumes, including the aforementioned 20-million-pound cutlery award.공시 • Aug 02Danimer Scientific, Inc. to Report Q2, 2024 Results on Aug 08, 2024Danimer Scientific, Inc. announced that they will report Q2, 2024 results After-Market on Aug 08, 2024공시 • Jun 13+ 14 more updatesDanimer Scientific, Inc.(UNQ:) dropped from Russell 2000 Value IndexDanimer Scientific, Inc.(UNQ:) dropped from Russell 2000 Value Index공시 • May 25Danimer Scientific, Inc. Receives Non-Compliance Notice from NYSE RegulationOn May 21, 2024, Danimer Scientific, Inc. (the Company") was notified by NYSE Regulation (NYSER") that the Company is not in compliance with the New York Stock Exchange's (NYSE") continued listing criteria under Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company's common stock was less than $1.00 over a consecutive 30 trading-day period as of May 20, 2024. The Company has notified the NYSE of its intent to cure the deficiency and return to compliance with the NYSE continued listing requirements. The Company will return to compliance if, during the six-month period following receipt of the NYSE notice, on the last trading-day of any calendar month, the Company's common stock has a closing share price of at least $1.00 and an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of that month. Under NYSE rules, the Company's common stock will continue to be traded on the NYSE during this period, subject to the Company's compliance with other applicable continued listing requirements. The NYSER notification does not affect the Company's business operations, Securities and Exchange Commission reporting requirements or debt obligations.Reported Earnings • May 08First quarter 2024 earnings released: US$0.26 loss per share (vs US$0.36 loss in 1Q 2023)First quarter 2024 results: US$0.26 loss per share (improved from US$0.36 loss in 1Q 2023). Revenue: US$10.2m (down 14% from 1Q 2023). Net loss: US$27.3m (loss narrowed 26% from 1Q 2023). Revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany.공시 • May 07Danimer Scientific Reveals New Branding and New Applications Based on PHA During NPE 2024Danimer Scientific, Inc. is unveiling new commercial applications and branding during NPE 2024, North America’s large plastics tradeshow, taking place this week in Orlando, FL. A more perfect polymer™ takes center stage at NPE 2024. Danimer’s signature PHA, Nodax®, represents a more perfect polymer revolution. PHAs (polyhydroxyalkanoates) are naturally made polymer chains, and at Danimer it harness microbes as tiny reactors to make its biopolymers, using canola oil as the renewable feedstock. The resulting PHA can be used to replace conventional plastics in uses from straws to lids, from coffee pods to flexible packaging, and from paper coatings to adhesives. With full PHA production capability in place, Danimer is poised for significant growth with commercial partners for several applications, including cutlery, flexible food packaging and paper packaging barrier coatings. Microbes, not Microplastics™ enables a new future for packaging items. Danimer is committed to offering solutions to address plastic pollution and the proliferation of microplastics. It is all about the microbes, both during origination and biodegradation. Microbes produce PHAs, and microbes biochemically recycle its PHAs, whether in industrial compost, home compost, soils, fresh water or the marine environment. Because a large class of microbes present in natural systems readily identify PHAs as a food source, there is no threat of residual microplastics. PHA grades are third party certified to fully biodegrade under various conditions, with the added benefit of no ecotoxicity concerns, PFAS or regulated metals. That makes Nodax a more perfect polymer™ for its planet.공시 • May 05Danimer Scientific, Inc., Annual General Meeting, Jul 09, 2024Danimer Scientific, Inc., Annual General Meeting, Jul 09, 2024.공시 • May 03Danimer Scientific, Inc. to Report Q1, 2024 Results on May 07, 2024Danimer Scientific, Inc. announced that they will report Q1, 2024 results After-Market on May 07, 2024New Risk • Apr 12New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €92.6m (US$98.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (18% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$73m net loss in 3 years). Shareholders have been diluted in the past year (12% increase in shares outstanding). Market cap is less than US$100m (€92.6m market cap, or US$98.6m).Reported Earnings • Mar 30Full year 2023 earnings released: US$1.52 loss per share (vs US$1.78 loss in FY 2022)Full year 2023 results: US$1.52 loss per share (improved from US$1.78 loss in FY 2022). Revenue: US$46.7m (down 12% from FY 2022). Net loss: US$155.5m (loss narrowed 14% from FY 2022). Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Chemicals industry in Germany.공시 • Mar 26Danimer Scientific, Inc. has completed a Follow-on Equity Offering in the amount of $14.999625 million.Danimer Scientific, Inc. has completed a Follow-on Equity Offering in the amount of $14.999625 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 11,250,000 Price\Range: $1 Discount Per Security: $0.07 Security Name: Warrants Security Type: Equity Warrant Securities Offered: 15,000,000 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 3,750,000 Price\Range: $0.9999 Discount Per Security: $0.06993 Transaction Features: Registered Direct OfferingNew Risk • Mar 24New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 12% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (18% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$92m net loss in 3 years). Shareholders have been diluted in the past year (12% increase in shares outstanding).공시 • Mar 21Danimer Scientific, Inc. has filed a Follow-on Equity Offering in the amount of $34.95 million.Danimer Scientific, Inc. has filed a Follow-on Equity Offering in the amount of $34.95 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 15,000,000 Price\Range: $1 Security Name: Warrants Security Type: Equity Warrant Securities Offered: 15,000,000 Price\Range: $1.33 Transaction Features: Registered Direct Offering공시 • Jan 31Danimer Scientific Receives Continued Listing Standard Notice from NYSEDanimer Scientific, Inc. announced that it received a notice from the New York Stock Exchange ('NYSE') on January 23, 2024, that the Company is not currently in compliance with the NYSE's continued listing standard requiring listed-company stock to maintain an average closing price of not less than $1.00 per share over a period of thirty (30) consecutive trading days. The Notice does not result in the immediate delisting of the Company's Common Stock from the NYSE. On January 26, 2024, the Company notified the NYSE that it intends to cure the stock price deficiency and return to compliance with the NYSE's minimum share price standard within the six-month period following receipt of the Notice. The Company's Common Stock will continue to be listed and trade on the NYSE during this period, subject to its compliance with other NYSE continued listing standards. The receipt of the Notice does not affect the Company's business, operations or reporting requirements with the Securities and Exchange Commission. The Company intends to consider all available options to cure its non-compliance with the NYSE minimum share price standard. The Company can regain compliance with the minimum share price requirement at any time during the six-month cure period if, on the last trading day of any calendar month during the cure period or on the last day of the cure period, the Company has (i) a closing share price of at least $1.00, and (ii) an average closing share price of at least $1.00 over the 30 trading-day periods ending on the last trading day of that month.공시 • Jan 19Danimer Scientific, Inc. Announces New DirectorsDanimer Scientific, Inc. announced that Dr. David Moody and Mr. Richard Altice have been appointed as members of Danimer’s Board of Directors. Dr. Moody’s appointment is effective immediately, and Mr. Altice’s appointment is effective as of April 15, 2024. Dr. David J. Moody currently is a member of the Board of Directors of Jadex Inc., a US-based manufacturing and material science company utilizing innovation and technology to develop sustainable products that serve the medical, industrial and consumer markets. Dr. Moody previously served as Chief Executive Officer of Jadex from March 2021 through July 2023, and before that served in various roles of increasing responsibility at Milliken & Company culminating in the role of Executive Vice President and Division President, Chemicals. Dr. Moody has over thirty years’ experience managing chemical and polymer related businesses in various leadership roles and holds a Bachelor of Science in Chemistry from Wofford College and a Ph.D. in Chemistry from the Georgia Institute of Technology. Richard N. Altice most recently retired from NatureWorks, a developer and manufacturer of biopolymers (polylactic acid), where he served as President and CEO for five years. Prior to NatureWorks, Mr. Altice was the Senior Vice President and President of PolyOne’s Designed Structures and Solutions, a polymer and plastics converting and food packaging business, formerly known as Spartech. Additionally, Mr. Altice was Vice President of Hexion’s Global Specialty Epoxy resin business and was formerly the President of Solutia’s Technical Specialties division, responsible for the global rubber chemicals and specialty fluids businesses. Mr. Altice has over thirty years of sales, marketing, operational and management experience in the specialty chemicals and biopolymer industries and holds a Bachelor of Science in Chemical Engineering from the Missouri University of Science and Technology. With these changes, Danimer’s Board will be comprised of eleven directors.Recent Insider Transactions • Nov 30Independent Director recently bought €85k worth of stockOn the 28th of November, Richard Hendrix bought around 100k shares on-market at roughly €0.85 per share. This transaction amounted to 29% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.New Risk • Nov 29New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €89.7m (US$98.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$92m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$93m net loss in 3 years). Market cap is less than US$100m (€89.7m market cap, or US$98.6m).Reported Earnings • Nov 15Third quarter 2023 earnings released: US$0.39 loss per share (vs US$0.94 loss in 3Q 2022)Third quarter 2023 results: US$0.39 loss per share (improved from US$0.94 loss in 3Q 2022). Revenue: US$10.9m (up 4.8% from 3Q 2022). Net loss: US$40.2m (loss narrowed 58% from 3Q 2022). Revenue is forecast to grow 52% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Chemicals industry in Germany.공시 • Nov 08Danimer Scientific, Inc. to Report Q3, 2023 Results on Nov 14, 2023Danimer Scientific, Inc. announced that they will report Q3, 2023 results After-Market on Nov 14, 2023공시 • Oct 20Danimer Scientific, BIOLO and Bolthouse Farms Announce Commercialization of Home Compostable Packaging for Fresh Produce with Meijer StoresDanimer Scientific, Inc. announced the commercialization of home compostable retail packaging for vegetables and fruit, which Danimer developed in partnership with biodegradable packaging and food service product manufacturer BIOLO and carrot producer Bolthouse Farms. Danimer’s signature PHA, Nodax®, was used to create the bags for one-pound Earthbound Farm Organic Mini Peeled Carrots, now available in Meijer’s regional network of 240 grocery stores and supercenters in six states across the Midwest. Danimer’s Nodax® is a biobased polyester made with oils derived from the seeds of plants such as canola. Unlike traditional plastic, which can take centuries to degrade, Danimer’s PHA-based products can degrade in a matter of months under certain conditions. The Earthbound Farm Organic Mini Peeled Carrots bags are certified as home compostable by TUV, a globally recognized leader in independent product testing, inspection and certification. This certification means that the bags have passed rigorous testing that requires them to disintegrate at least 90% within 26 weeks and biodegrade within 52 weeks under home compost conditions.Reported Earnings • Aug 09Second quarter 2023 earnings released: US$0.39 loss per share (vs US$0.30 loss in 2Q 2022)Second quarter 2023 results: US$0.39 loss per share (further deteriorated from US$0.30 loss in 2Q 2022). Revenue: US$12.9m (up 1.3% from 2Q 2022). Net loss: US$39.2m (loss widened 29% from 2Q 2022). Revenue is forecast to grow 47% p.a. on average during the next 3 years, compared to a 1.8% growth forecast for the Chemicals industry in Germany.공시 • Aug 01Danimer Scientific, Inc. to Report Q2, 2023 Results on Aug 08, 2023Danimer Scientific, Inc. announced that they will report Q2, 2023 results After-Market on Aug 08, 2023New Risk • Jul 03New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$172m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$172m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$112m net loss in 3 years).Reported Earnings • May 11First quarter 2023 earnings released: US$0.36 loss per share (vs US$0.26 loss in 1Q 2022)First quarter 2023 results: US$0.36 loss per share (further deteriorated from US$0.26 loss in 1Q 2022). Revenue: US$11.9m (down 19% from 1Q 2022). Net loss: US$36.6m (loss widened 39% from 1Q 2022). Revenue is forecast to grow 48% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Chemicals industry in Germany.공시 • May 04Danimer Scientific, Inc. to Report Q1, 2023 Results on May 10, 2023Danimer Scientific, Inc. announced that they will report Q1, 2023 results at 4:00 PM, US Eastern Standard Time on May 10, 2023Reported Earnings • Mar 30Full year 2022 earnings released: US$1.78 loss per share (vs US$0.65 loss in FY 2021)Full year 2022 results: US$1.78 loss per share (further deteriorated from US$0.65 loss in FY 2021). Revenue: US$53.2m (down 9.4% from FY 2021). Net loss: US$179.8m (loss widened 199% from FY 2021). Revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 1.8% growth forecast for the Chemicals industry in Germany.Reported Earnings • Nov 10Third quarter 2022 earnings released: US$0.94 loss per share (vs US$0.08 profit in 3Q 2021)Third quarter 2022 results: US$0.94 loss per share (down from US$0.08 profit in 3Q 2021). Revenue: US$10.4m (down 22% from 3Q 2021). Net loss: US$94.9m (down US$102.7m from profit in 3Q 2021). Revenue is forecast to grow 59% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to remain flat.Recent Insider Transactions • Aug 24Director recently sold €869k worth of stockOn the 19th of August, Stuart Pratt sold around 175k shares on-market at roughly €4.96 per share. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.Reported Earnings • Aug 11Second quarter 2022 earnings released: US$0.30 loss per share (vs US$0.44 profit in 2Q 2021)Second quarter 2022 results: US$0.30 loss per share (down from US$0.44 profit in 2Q 2021). Revenue: US$12.7m (down 12% from 2Q 2021). Net loss: US$30.4m (down 178% from profit in 2Q 2021). Over the next year, revenue is forecast to grow 85%, compared to a 3.6% growth forecast for the industry in Germany.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 6CU0 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: 6CU0 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Danimer Scientific 배당 수익률 vs 시장6CU0의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (6CU0)n/a시장 하위 25% (DE)1.5%시장 상위 25% (DE)4.5%업계 평균 (Chemicals)3.7%분석가 예측 (6CU0) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 6CU0 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 6CU0 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 6CU0 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: 6CU0 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YDE 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/02/09 22:00종가2024/11/12 00:00수익2024/09/30연간 수익2023/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Danimer Scientific, Inc.는 1명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Laurence AlexanderJefferies LLC
공시 • Apr 18+ 1 more updateBidding Procedure Approved for Danimer Scientific, Inc.The US Bankruptcy Court gave an order approving the bidding procedures relating to the sale of the substantially all the assets of Danimer Scientific, Inc. on April 17, 2025. The Court approved for the sale of substantially all the assets to the successful bidder through auction. To qualify as a qualified bidder, interested parties should submit their bids by May 2, 2025, along with good-faith deposit in the amount of 10% of the bid price. The initial minimum overbid should be at least $0.5 million. If the debtor receives any qualified bids, then it would hold an auction for its assets on May 5, 2025. At the auction, the subsequent bids would be in increments of $0.5 million. The stalking horse bidder would be entitled to a break-up fee of 3%. The sale hearing is scheduled for May 12, 2025. Sale closing is on May 16, 2025.
공시 • Apr 15Motion for sale of De Minimis Asset Sale Approved for Danimer Scientific, Inc.The US Bankruptcy Court gave an order approving the sale procedures relating to the sale of De Minimis assets of Danimer Scientific, Inc on April 14, 2025. As per the order the debtors is authorized to sell de minimis assets for $0.25 million or less in total consideration or value in one or a series of related transactions without further notice or court approval after providing notice of the sale to certain parties in accordance with the following procedures. With regard to a De Minimis transaction with a net selling price less than or equal to $2 million, the debtor shall give written notice of each de Minimis transaction to notice parties. The sale notice shall be filed and sent to the notice parties by e-mail, facsimile, or first-class mail at least 7 business days prior to the closing of such de Minimis transaction. With regard to a De Minimis Transaction with a selling price of greater than $2 million, the debtor shall give a sale notice to the notice parties and all other parties required receiving notice under Bankruptcy Rule 2002(a) (2). The sale notice shall be filed and sent to the 2002 parties by e-mail, facsimile, or first-class mail at least 7 calendar days prior to the closing of such de Minimis transaction. Any objections to the De Minimis Transaction must be in writing, state the grounds for the objection with specificity, and be filed and served so as to be actually received on or before the Closing Date. If a sale objection is properly filed and served by the sale objection deadline, and the debtor and the objecting party are unable to reach an agreement among themselves, then the relevant de Minimis asset shall be sold or otherwise transferred only upon further order of this court, after notice and a hearing; provided, however, that the debtor, with the agreement of the relevant proposed counterparty, may consummate any portion of the de Minimis transaction that is not the subject of a sale objection on or after the expiration of the sale objection deadline. If no sale objection is properly filed and served by the sale objection deadline, then the debtor, without further order of the court, is authorized, but not directed, to consummate the de Minimis transaction immediately, and take such other actions as necessary to close such transaction and collect the proceeds thereof.
공시 • Mar 28Motion for Asset Sale Filed by Danimer Scientific, Inc.Danimer Scientific, Inc filed a motion in the US Bankruptcy Court for the sale of its substantially all its assets on March 27, 2025. The debtor seeks the Court’s approval for the sale of its substantially all its assets to successful bidder. To qualify as a qualified bidder, interested parties should submit their bids by May 2, 2025, along with good-faith deposit in the amount of 10% of the bid price. The initial minimum overbid should be at least $0.5 million. The debtor has scheduled an auction on May 5, 2025. At the auction, the subsequent bids would be in increments of $0.5 million. The stalking horse bidder would be entitled to a break-up fee of 3%. The sale hearing is scheduled for May 12, 2025. Sale closing is on May 16, 2025.
공시 • Mar 19+ 1 more updateMotion for Joint Administration Filed by Danimer Scientific, Inc.Danimer Scientific, Inc., along with its affiliates, filed a motion for joint administration of their Chapter 11 bankruptcy cases in the US Bankruptcy Court on March 18, 2025. As per the motion, the debtor seeks the joint administration of the cases of its affiliates, Danimer Bioplastics, Inc., Danimer Scientific Holdings, LLC, Danimer Scientific Kentucky, Inc., Danimer Scientific Manufacturing, Inc., Danimer Scientific, L.L.C. Meredian Bioplastics, Inc., Meredian Holdings Group, Inc., Meredian, Inc. and Novomer, Inc., with its own case for administrative and procedural purposes. Danimer Scientific, Inc. has been proposed as the lead debtor.
공시 • Dec 18Danimer Scientific, Inc. announced that it expects to receive $11.25 million in fundingDanimer Scientific, Inc. announced that it has entered into a super senior secured uninsured promissory note agreement with certain lenders under its existing term loan financing agreement, as well as certain additional lenders for a secured loan for a principal amount of $11,250,000 in exchange for cash, net of a 5% upfront fee and other fees and expenses on December 17, 2024. The secured loan matures on December 17, 2026, and accrues interest at 15% per annum, which interest shall be paid in kind on a quarterly basis. Prepayment of the secured loan is subject to payment of premiums of (i) prior to December 17, 2025, 30% and (ii) on or after December 17, 2025, and before maturity, 10%.
공시 • Dec 04Danimer Scientific, Inc. Announces Resignation of Cynthia Cohen as A DirectorDanimer Scientific, Inc. announced that effective as of December 1, 2024, Cynthia Cohen resigned as a director of the Company. Ms. Cohen’s resignation was not because of any disagreement with the Company.
공시 • Nov 16Danimer Scientific, Inc. announced delayed 10-Q filingOn 11/15/2024, Danimer Scientific, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Nov 05Danimer Scientific Announces Intention to Complete a Reverse Stock Split to Regain Compliance with the Price Criteria of Section 802.01C of the NYSE Listed Company ManualDanimer Scientific, Inc. announced that, following approval by the Company's stockholders and its Board of Directors, the Company will effect a reverse stock split ('Reverse Stock Split') of Danimer's Class A common stock, par value $0.0001 per share ('Common Stock'), at a ratio of 1-for-40 (the 'Reverse Stock Split Ratio'), which ratio was determined by the Board of Directors from within a range of ratios authorized by the stockholders. The Reverse Stock Split is expected to become effective on November 12, 2024, after close of trading on the New York Stock Exchange ('NYSE'). The Common Stock is expected to begin trading on a split-adjusted basis when the markets open on November 13, 2024, under the existing trading symbol 'DNMR' and new CUSIP number (236272 407). The Company believes the Reverse Stock Split will increase the price per share of the Common Stock and thus enable it to regain compliance with the price criteria of Section 802.01C of the NYSE Listed Company Manual (the 'Minimum Share Price Rule').
Board Change • Nov 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Special Advisor & Director Stephen Croskrey was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
공시 • Oct 28Danimer Scientific Announces Second Circuit Court Affirms Dismissal of Class Action LawsuitDanimer Scientific, Inc. announced that, on September 27, 2024, the United States Court of Appeals for the Second Circuit affirmed the 2023 Order of the United States District Court for the Eastern District of New York dismissing a previously disclosed putative class action complaint captioned In re Danimer Scientific, Inc. Securities Litigation. Subsequently, the plaintiffs in the three shareholder derivative cases that had been pending in state and federal courts in Delaware, which cases had been stayed pending the outcome of the Second Circuit case, dismissed their complaints.
공시 • Oct 15+ 2 more updatesDanimer Scientific, Inc. to Report Q3, 2024 Results on Nov 14, 2024Danimer Scientific, Inc. announced that they will report Q3, 2024 results After-Market on Nov 14, 2024
Reported Earnings • Aug 09Second quarter 2024 earnings released: US$0.20 loss per share (vs US$0.39 loss in 2Q 2023)Second quarter 2024 results: US$0.20 loss per share (improved from US$0.39 loss in 2Q 2023). Revenue: US$7.63m (down 41% from 2Q 2023). Net loss: US$22.7m (loss narrowed 42% from 2Q 2023). Revenue is forecast to grow 44% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Chemicals industry in Germany.
공시 • Aug 09Danimer Scientific, Inc. Provides Financial Guidance for the Second Quarter of Fiscal 2025Danimer Scientific, Inc. provides financial guidance for the second quarter of fiscal 2025. For the period, the company expects annualized PHA revenues to more than triple, based solely on demand from existing customer relationships and their indicated volumes, including the aforementioned 20-million-pound cutlery award.
공시 • Aug 02Danimer Scientific, Inc. to Report Q2, 2024 Results on Aug 08, 2024Danimer Scientific, Inc. announced that they will report Q2, 2024 results After-Market on Aug 08, 2024
공시 • Jun 13+ 14 more updatesDanimer Scientific, Inc.(UNQ:) dropped from Russell 2000 Value IndexDanimer Scientific, Inc.(UNQ:) dropped from Russell 2000 Value Index
공시 • May 25Danimer Scientific, Inc. Receives Non-Compliance Notice from NYSE RegulationOn May 21, 2024, Danimer Scientific, Inc. (the Company") was notified by NYSE Regulation (NYSER") that the Company is not in compliance with the New York Stock Exchange's (NYSE") continued listing criteria under Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company's common stock was less than $1.00 over a consecutive 30 trading-day period as of May 20, 2024. The Company has notified the NYSE of its intent to cure the deficiency and return to compliance with the NYSE continued listing requirements. The Company will return to compliance if, during the six-month period following receipt of the NYSE notice, on the last trading-day of any calendar month, the Company's common stock has a closing share price of at least $1.00 and an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of that month. Under NYSE rules, the Company's common stock will continue to be traded on the NYSE during this period, subject to the Company's compliance with other applicable continued listing requirements. The NYSER notification does not affect the Company's business operations, Securities and Exchange Commission reporting requirements or debt obligations.
Reported Earnings • May 08First quarter 2024 earnings released: US$0.26 loss per share (vs US$0.36 loss in 1Q 2023)First quarter 2024 results: US$0.26 loss per share (improved from US$0.36 loss in 1Q 2023). Revenue: US$10.2m (down 14% from 1Q 2023). Net loss: US$27.3m (loss narrowed 26% from 1Q 2023). Revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany.
공시 • May 07Danimer Scientific Reveals New Branding and New Applications Based on PHA During NPE 2024Danimer Scientific, Inc. is unveiling new commercial applications and branding during NPE 2024, North America’s large plastics tradeshow, taking place this week in Orlando, FL. A more perfect polymer™ takes center stage at NPE 2024. Danimer’s signature PHA, Nodax®, represents a more perfect polymer revolution. PHAs (polyhydroxyalkanoates) are naturally made polymer chains, and at Danimer it harness microbes as tiny reactors to make its biopolymers, using canola oil as the renewable feedstock. The resulting PHA can be used to replace conventional plastics in uses from straws to lids, from coffee pods to flexible packaging, and from paper coatings to adhesives. With full PHA production capability in place, Danimer is poised for significant growth with commercial partners for several applications, including cutlery, flexible food packaging and paper packaging barrier coatings. Microbes, not Microplastics™ enables a new future for packaging items. Danimer is committed to offering solutions to address plastic pollution and the proliferation of microplastics. It is all about the microbes, both during origination and biodegradation. Microbes produce PHAs, and microbes biochemically recycle its PHAs, whether in industrial compost, home compost, soils, fresh water or the marine environment. Because a large class of microbes present in natural systems readily identify PHAs as a food source, there is no threat of residual microplastics. PHA grades are third party certified to fully biodegrade under various conditions, with the added benefit of no ecotoxicity concerns, PFAS or regulated metals. That makes Nodax a more perfect polymer™ for its planet.
공시 • May 05Danimer Scientific, Inc., Annual General Meeting, Jul 09, 2024Danimer Scientific, Inc., Annual General Meeting, Jul 09, 2024.
공시 • May 03Danimer Scientific, Inc. to Report Q1, 2024 Results on May 07, 2024Danimer Scientific, Inc. announced that they will report Q1, 2024 results After-Market on May 07, 2024
New Risk • Apr 12New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €92.6m (US$98.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (18% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$73m net loss in 3 years). Shareholders have been diluted in the past year (12% increase in shares outstanding). Market cap is less than US$100m (€92.6m market cap, or US$98.6m).
Reported Earnings • Mar 30Full year 2023 earnings released: US$1.52 loss per share (vs US$1.78 loss in FY 2022)Full year 2023 results: US$1.52 loss per share (improved from US$1.78 loss in FY 2022). Revenue: US$46.7m (down 12% from FY 2022). Net loss: US$155.5m (loss narrowed 14% from FY 2022). Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Chemicals industry in Germany.
공시 • Mar 26Danimer Scientific, Inc. has completed a Follow-on Equity Offering in the amount of $14.999625 million.Danimer Scientific, Inc. has completed a Follow-on Equity Offering in the amount of $14.999625 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 11,250,000 Price\Range: $1 Discount Per Security: $0.07 Security Name: Warrants Security Type: Equity Warrant Securities Offered: 15,000,000 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 3,750,000 Price\Range: $0.9999 Discount Per Security: $0.06993 Transaction Features: Registered Direct Offering
New Risk • Mar 24New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 12% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (18% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$92m net loss in 3 years). Shareholders have been diluted in the past year (12% increase in shares outstanding).
공시 • Mar 21Danimer Scientific, Inc. has filed a Follow-on Equity Offering in the amount of $34.95 million.Danimer Scientific, Inc. has filed a Follow-on Equity Offering in the amount of $34.95 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 15,000,000 Price\Range: $1 Security Name: Warrants Security Type: Equity Warrant Securities Offered: 15,000,000 Price\Range: $1.33 Transaction Features: Registered Direct Offering
공시 • Jan 31Danimer Scientific Receives Continued Listing Standard Notice from NYSEDanimer Scientific, Inc. announced that it received a notice from the New York Stock Exchange ('NYSE') on January 23, 2024, that the Company is not currently in compliance with the NYSE's continued listing standard requiring listed-company stock to maintain an average closing price of not less than $1.00 per share over a period of thirty (30) consecutive trading days. The Notice does not result in the immediate delisting of the Company's Common Stock from the NYSE. On January 26, 2024, the Company notified the NYSE that it intends to cure the stock price deficiency and return to compliance with the NYSE's minimum share price standard within the six-month period following receipt of the Notice. The Company's Common Stock will continue to be listed and trade on the NYSE during this period, subject to its compliance with other NYSE continued listing standards. The receipt of the Notice does not affect the Company's business, operations or reporting requirements with the Securities and Exchange Commission. The Company intends to consider all available options to cure its non-compliance with the NYSE minimum share price standard. The Company can regain compliance with the minimum share price requirement at any time during the six-month cure period if, on the last trading day of any calendar month during the cure period or on the last day of the cure period, the Company has (i) a closing share price of at least $1.00, and (ii) an average closing share price of at least $1.00 over the 30 trading-day periods ending on the last trading day of that month.
공시 • Jan 19Danimer Scientific, Inc. Announces New DirectorsDanimer Scientific, Inc. announced that Dr. David Moody and Mr. Richard Altice have been appointed as members of Danimer’s Board of Directors. Dr. Moody’s appointment is effective immediately, and Mr. Altice’s appointment is effective as of April 15, 2024. Dr. David J. Moody currently is a member of the Board of Directors of Jadex Inc., a US-based manufacturing and material science company utilizing innovation and technology to develop sustainable products that serve the medical, industrial and consumer markets. Dr. Moody previously served as Chief Executive Officer of Jadex from March 2021 through July 2023, and before that served in various roles of increasing responsibility at Milliken & Company culminating in the role of Executive Vice President and Division President, Chemicals. Dr. Moody has over thirty years’ experience managing chemical and polymer related businesses in various leadership roles and holds a Bachelor of Science in Chemistry from Wofford College and a Ph.D. in Chemistry from the Georgia Institute of Technology. Richard N. Altice most recently retired from NatureWorks, a developer and manufacturer of biopolymers (polylactic acid), where he served as President and CEO for five years. Prior to NatureWorks, Mr. Altice was the Senior Vice President and President of PolyOne’s Designed Structures and Solutions, a polymer and plastics converting and food packaging business, formerly known as Spartech. Additionally, Mr. Altice was Vice President of Hexion’s Global Specialty Epoxy resin business and was formerly the President of Solutia’s Technical Specialties division, responsible for the global rubber chemicals and specialty fluids businesses. Mr. Altice has over thirty years of sales, marketing, operational and management experience in the specialty chemicals and biopolymer industries and holds a Bachelor of Science in Chemical Engineering from the Missouri University of Science and Technology. With these changes, Danimer’s Board will be comprised of eleven directors.
Recent Insider Transactions • Nov 30Independent Director recently bought €85k worth of stockOn the 28th of November, Richard Hendrix bought around 100k shares on-market at roughly €0.85 per share. This transaction amounted to 29% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
New Risk • Nov 29New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €89.7m (US$98.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$92m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$93m net loss in 3 years). Market cap is less than US$100m (€89.7m market cap, or US$98.6m).
Reported Earnings • Nov 15Third quarter 2023 earnings released: US$0.39 loss per share (vs US$0.94 loss in 3Q 2022)Third quarter 2023 results: US$0.39 loss per share (improved from US$0.94 loss in 3Q 2022). Revenue: US$10.9m (up 4.8% from 3Q 2022). Net loss: US$40.2m (loss narrowed 58% from 3Q 2022). Revenue is forecast to grow 52% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Chemicals industry in Germany.
공시 • Nov 08Danimer Scientific, Inc. to Report Q3, 2023 Results on Nov 14, 2023Danimer Scientific, Inc. announced that they will report Q3, 2023 results After-Market on Nov 14, 2023
공시 • Oct 20Danimer Scientific, BIOLO and Bolthouse Farms Announce Commercialization of Home Compostable Packaging for Fresh Produce with Meijer StoresDanimer Scientific, Inc. announced the commercialization of home compostable retail packaging for vegetables and fruit, which Danimer developed in partnership with biodegradable packaging and food service product manufacturer BIOLO and carrot producer Bolthouse Farms. Danimer’s signature PHA, Nodax®, was used to create the bags for one-pound Earthbound Farm Organic Mini Peeled Carrots, now available in Meijer’s regional network of 240 grocery stores and supercenters in six states across the Midwest. Danimer’s Nodax® is a biobased polyester made with oils derived from the seeds of plants such as canola. Unlike traditional plastic, which can take centuries to degrade, Danimer’s PHA-based products can degrade in a matter of months under certain conditions. The Earthbound Farm Organic Mini Peeled Carrots bags are certified as home compostable by TUV, a globally recognized leader in independent product testing, inspection and certification. This certification means that the bags have passed rigorous testing that requires them to disintegrate at least 90% within 26 weeks and biodegrade within 52 weeks under home compost conditions.
Reported Earnings • Aug 09Second quarter 2023 earnings released: US$0.39 loss per share (vs US$0.30 loss in 2Q 2022)Second quarter 2023 results: US$0.39 loss per share (further deteriorated from US$0.30 loss in 2Q 2022). Revenue: US$12.9m (up 1.3% from 2Q 2022). Net loss: US$39.2m (loss widened 29% from 2Q 2022). Revenue is forecast to grow 47% p.a. on average during the next 3 years, compared to a 1.8% growth forecast for the Chemicals industry in Germany.
공시 • Aug 01Danimer Scientific, Inc. to Report Q2, 2023 Results on Aug 08, 2023Danimer Scientific, Inc. announced that they will report Q2, 2023 results After-Market on Aug 08, 2023
New Risk • Jul 03New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$172m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$172m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$112m net loss in 3 years).
Reported Earnings • May 11First quarter 2023 earnings released: US$0.36 loss per share (vs US$0.26 loss in 1Q 2022)First quarter 2023 results: US$0.36 loss per share (further deteriorated from US$0.26 loss in 1Q 2022). Revenue: US$11.9m (down 19% from 1Q 2022). Net loss: US$36.6m (loss widened 39% from 1Q 2022). Revenue is forecast to grow 48% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Chemicals industry in Germany.
공시 • May 04Danimer Scientific, Inc. to Report Q1, 2023 Results on May 10, 2023Danimer Scientific, Inc. announced that they will report Q1, 2023 results at 4:00 PM, US Eastern Standard Time on May 10, 2023
Reported Earnings • Mar 30Full year 2022 earnings released: US$1.78 loss per share (vs US$0.65 loss in FY 2021)Full year 2022 results: US$1.78 loss per share (further deteriorated from US$0.65 loss in FY 2021). Revenue: US$53.2m (down 9.4% from FY 2021). Net loss: US$179.8m (loss widened 199% from FY 2021). Revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 1.8% growth forecast for the Chemicals industry in Germany.
Reported Earnings • Nov 10Third quarter 2022 earnings released: US$0.94 loss per share (vs US$0.08 profit in 3Q 2021)Third quarter 2022 results: US$0.94 loss per share (down from US$0.08 profit in 3Q 2021). Revenue: US$10.4m (down 22% from 3Q 2021). Net loss: US$94.9m (down US$102.7m from profit in 3Q 2021). Revenue is forecast to grow 59% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to remain flat.
Recent Insider Transactions • Aug 24Director recently sold €869k worth of stockOn the 19th of August, Stuart Pratt sold around 175k shares on-market at roughly €4.96 per share. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
Reported Earnings • Aug 11Second quarter 2022 earnings released: US$0.30 loss per share (vs US$0.44 profit in 2Q 2021)Second quarter 2022 results: US$0.30 loss per share (down from US$0.44 profit in 2Q 2021). Revenue: US$12.7m (down 12% from 2Q 2021). Net loss: US$30.4m (down 178% from profit in 2Q 2021). Over the next year, revenue is forecast to grow 85%, compared to a 3.6% growth forecast for the industry in Germany.